Skip to main content

Table 1 Patient characteristics

From: In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis

  Controls (n = 20) TREACH (n = 38) FLARE (n = 37)
Female gender, n (%) 10 (50) 25 (65.8) 25 (67.6)
Age in years, mean (SD) 31.8 (9.7) 53.3 (13.98)a 53.7 (13.40)a
Disease duration in months, median (range) - 5.4 (2-12) 73.0 (0-414)b
Presence of joint erosions, n (%) - 10 (26.3) 20 (54.1)c
Anti-CCP positive, n (%) - 30 (78.9) 24 (85.7)d
Rheumatoid factor (IgM) positive, n (%) - 31 (81.6) 27 (73.0)
DAS44 at baseline, mean (SD) - 3.05 (0.92) 3.57 (0.95)c
HAQ-DI at baseline, mean (SD) - - 1.43 (0.62)
Use of NSAID, n (%) - 25 (67.6) 19 (51.4)
Use of methotrexate, n (%) - - 22 (59.5)
Use of hydroxychloroquine, n (%) - - 11 (29.7)
Use of sulfasalazine, n (%) - - 5 (13.5)
Number of DMARDs, median (range) - - 1 (0-3)e
Use of anti-TNF-α therapy, n (%) - - 5 (13.5)
  1. DAS44, Disease Activity Score, 44 joints; HAQ-DI, Health Assessment Questionnaire Disability Index. aP < 0.001 as compared with healthy controls; bP < 0.001 as compared with tREACH patients; cP < 0.05; danti-CCP was not routinely analyzed; percentage is based on 28 patients with known anti-CCP status; eSeven patients were not using any DMARD at the time of assessment.